Avsar.

Healthcare · Pharmaceuticals

Corona Remedies Ltd (CORONA)

₹2,113.00

Mkt cap
₹12,923 Cr
P/E ratio
64.80
P/B
17.32
Div yield
0.47%
ROE
29.50%
ROCE
33.30%
EPS (TTM)
₹32.61
Book value
₹122
52W range
1,348–2,113
Sector
Healthcare

Incorporated in August 2004, Corona Remedies Limited is a pharmaceutical company developing, manufacturing, and marketing products in women’s healthcare, cardiology, pain management, urology, and other therapeutic areas. [1]

NSE CORONABSE 544644www.coronaremedies.com
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsNeutral
52-week range
0.00% from high
₹2,113
₹1,348+56.79% from low₹2,113
Current
₹2,113.00
Prev close
₹2,105.40
Day
+0.36%
Price performance
1D
+0.36%
1W
+3.27%
1M
+11.60%
3M
+29.36%
6M
+44.85%
1Y
—
YTD
+46.38%

Financials

F
Revenue, profit & margin
P/E ratio
64.8×
CORONA is 90% above the sector median of 34.0×
CORONA64.8×
Sector median34.0×
 Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Trend
Sales314298294347361342353
Expenses247228239277283259291
Operating Profit67695470788362
OPM %21%23%18%20%22%24%18%
Other Income21122-174
Interest3222221
Depreciation9101099910
Profit before tax57584361705554
Tax %25%23%28%24%25%25%17%
Net Profit43453146524145
EPS in Rs7.037.325.127.598.536.747.37
Raw PDF

Earnings

EResults dates & reactions
Next results
31 Jul '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

No reaction history yet.
No quarterly filings ingested yet.

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Jun 2026
69.00%Promoter
Promoters69.00%
FIIs3.63%1.38
DIIs12.90%5.88
Public14.47%7.28
Ownership trend

Peers

P8 companies
Valuation vs quality
P/E × ROCE · bubble = market cap
NameCMPP/EMkt CapDiv YldNP QtrQtr Profit VarSales QtrQtr Sales VarROCE
Sun Pharma.Inds.₹1,941.1037.484,65,7350.82%2,710+13.58%14,612+12.76%20.53%
Divi's Lab.₹7,248.5073.361,92,4250.41%751+13.44%2,831+9.52%21.97%
Torrent Pharma.₹4,961.5086.111,88,7200.77%364−20.58%4,197+41.84%15.19%
Cipla₹1,410.6031.841,13,9550.92%786−39.19%7,119+2.33%15.49%
Zydus Lifesci.₹1,108.7020.381,10,5930.09%1,341+21.92%7,587+16.22%21.14%
Lupin₹2,370.5019.061,08,3870.76%1,469+101.49%7,475+31.89%29.93%
Mankind Pharma₹2,507.2051.441,03,5460.04%559+34.23%3,443+11.81%13.53%
Corona Remedies₹2,113.0064.7512,9230.47%45+43.75%353+20.23%33.29%
Median: 157 Co.₹432.0534.031,9780.10%15+28.10%176+17.66%15.10%

Filings

D
Annual reports1
Financial Year 2026bse
Concall transcripts7
TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptJan 2026PPTJan 2026RECJan 2026
Credit ratings1
Rating update 9 Febcare
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2dBoard Meeting Intimation for Consideration And Approval Of Unaudited Financial Results On Standalone And Consolidated Basis For First Quarter And Three Months Ended June 30, 2026 17 Jul - Board meets July 31, 2026 to consider Q1 FY27 standalone and consolidated results; trading window closed till Aug. 2.Shareholders Meeting / Postal Ballot- Scrutinizer''s Report 10 Jul - 22nd AGM resolutions passed; ₹10 final dividend approved for FY26.Shareholder Meeting / Postal Ballot-Outcome of AGM 9 Jul - 22nd AGM held on July 09, 2026; shareholders approved ₹10 final dividend and key appointments.Compliances-Certificate Under Reg. 74(5) Of SEBI (DP) Regulations, 2018 6 Jul - Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the first quarter ended June 30, 2026